Syncona Shs GBP (GB:SYNC) has released an update.
Beacon Therapeutics, a Syncona portfolio company, revealed promising 36-month clinical trial results for their gene therapy treatment, AGTC-501, for X-linked retinitis pigmentosa (XLRP). The data, presented at the EURETINA conference, showed that AGTC-501 is well-tolerated and continues to demonstrate a positive difference in visual function. These results support the ongoing development of AGTC-501, with future updates expected from the Phase II SKYLINE trial later in the year.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
